Meteospasmyl, 60 mg+300 mg capsules 60 pcs

ATX code: [A03AX58]

Pharmacotherapeutic group

Spasmolytic medicine.

Pharmacological properties

A combined drug. It has antispasmodic effect, reduces gas in the intestine.

Alverine is myotropic antispasmodic whose action is not accompanied by atropine-like effect or ganglioblocating activity. It reduces the increased tone of the smooth muscles of the intestine.

Simethicone is hydrophobic polymeric substance with low surface tension, which reduces gas formation in the intestine and covers the walls of the digestive tract with a protective film.

Indications

Gastrointestinal functional disorders manifested by abdominal pain, flatulence, belching, nausea, constipation, diarrhea, or alternation of these.

Preparing for radiological, ultrasonic or instrumental examination of the abdominal cavity.

Active ingredient

Composition

The active ingredients:

Alverine citrate 60 mg,

Simethicone 300 mg.

The composition of the shell:

Gelatin 167.02 mg,

Glycerol 84.12 mg,

Titanium dioxide 1.86 mg,

Purified water q.s.

How to take, the dosage

Internally. 1 capsule 2-3 times a day before meals.

In preparation for the study of the abdominal cavity – 1 capsule 2-3 times the day before the study and 1 capsule in the morning on the day of the study.

The duration of therapy is determined by the doctor individually.

Interaction

Special Instructions

In patients receiving alverine/simethicone, elevated levels of hepatic alanine aminotransferase and asparagine aminotransferase enzymes have been reported. This may be associated with a simultaneous increase in the level of total bilirubin in blood serum. If the level of liver aminotransferases increases to values exceeding 3 or more times the upper threshold values, as well as in case of jaundice development, the drug treatment should be stopped.

Influence on the ability to drive and operate vehicles

The drug has little effect on the ability to drive and operate vehicles. In some patients, dizziness has been registered during the use of the drug. Disorders of this type may affect the ability to operate vehicles and mechanisms.

Synopsis

Contraindications

Side effects

The frequency of adverse reactions was determined according to World Health Organization recommendations:

Very common: (≥1/10)

Frequent: (≥1/100 to < 1/10)

Infrequent: (≥1/1000 to < 1/100)

Rare: (≥1/10000 to < 1/1000)

Very rare, including individual reports: (< 1/10,000)

Frequency not determined: frequency cannot be estimated from available data.

Liver and biliary tract disorders

Very rare: Cytolytic hepatitis.

Laboratory and instrumental findings

Frequency not determined: increased levels of transaminases, alkaline phosphatase and bilirubin.

Dermatological and subcutaneous tissue disorders

Infrequency not determined: angioedema, skin rash, urticaria and itching.

Immune system disorders

Very rare: anaphylactic type reactions, anaphylactic shock.

Hearing and balance disorders

Frequency not determined: dizziness.

Nervous system disorders

Frequency not determined: headache.

Gastrointestinal tract disorders

Prevalence not determined: nausea.

If these, or any other adverse reactions occur when using the drug, a physician should be consulted.

Notification if side effects are suspected

It is important to report side effects after the drug is registered to ensure continued monitoring of the drug’s risk/benefit ratio. Healthcare professionals are asked to report all adverse events observed while using the drug through national adverse reaction reporting systems and/or to the company address listed below.

Overdose

Cases of vertigo have been reported when doses significantly higher than recommended.

Appropriate supportive measures should be taken if an overdose is suspected. These measures include observation of the patient and symptomatic treatment, if necessary.

Pregnancy use